Decision Resources, Inc.

Forecast: Pneumonia drug market will be supported by uptake of new therapies

Published in Biotech Law Weekly, November 19th, 2004

Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, despite the patent expiry of key antibiotics in the next 10 years, the community-acquired pneumonia drug market will be supported by increasing drug resistance and the uptake of new and recently launched products.

The new Pharmacor study entitled "Community-Acquired Pneumonia" lists Pfizer's Zithromax, Abbott's Biaxin/Klacid, Roche's Rocephin, and Johnson & Johnson's Levaquin as major antibiotics that will face generic competition.

The study also finds that drug sales in the highly saturated, increasingly competitive market...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-11-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry